Medical News

January 28 2004–Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that f HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world?s population.

Scope
Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population

Overview of the limitations surrounding co-morbid management such as recognition of co
infection, high-risk groups and lack of efficacious antivirals

Report Highlights
Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing
the lifespan of this co-morbid population. Effective treatment is currently hampered by
poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines.

Reasons to Purchase
Effectively target this niche sector, through a complete understanding of the prevalence
of the co-morbid population in the seven major markets

Identify the most promising products in the HIV and HBV pipelines, and track how current
players are seeking to optimize their market share

For a complete index of this report click on
http://www.researchandmarkets.com/reports/42806

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute
thousands of major research publications from the world’s leading publishers, consultants
and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com

January 28 2004–Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that f HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world?s population.

Scope
Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population

Overview of the limitations surrounding co-morbid management such as recognition of co
infection, high-risk groups and lack of efficacious antivirals

Report Highlights
Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing
the lifespan of this co-morbid population. Effective treatment is currently hampered by
poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines.

Reasons to Purchase
Effectively target this niche sector, through a complete understanding of the prevalence
of the co-morbid population in the seven major markets

Identify the most promising products in the HIV and HBV pipelines, and track how current
players are seeking to optimize their market share

For a complete index of this report click on
http://www.researchandmarkets.com/reports/42806

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute
thousands of major research publications from the world’s leading publishers, consultants
and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com